NYSE$USNA

USANA Health Sciences Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported a decrease in net sales and diluted EPS due to challenging operating environment in Asia Pacific and strengthening U.S. dollar.

USANA Health Sciences reported a decrease in net sales to $233 million compared to $274 million in the prior year quarter. Diluted EPS also decreased to $0.78 versus $1.36 in the third quarter of 2021. The company revised its fiscal year 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively.

  • Third quarter net sales were $233 million, a 15% decrease compared to the prior-year quarter.
  • Third quarter diluted EPS totaled $0.78, a 43% decrease compared to the third quarter of 2021.
  • The company generated $29 million in operating cash flow and ended the quarter with $247 million in cash and cash equivalents, remaining debt-free.
  • Management is evaluating and executing several short-term initiatives to regain momentum, including new incentives and increased in-person communications.

Headline financials

Total Revenue

$233M

Previous: $274M-15.0%
EPS (adj)

$0.78

Previous: $1.36-42.6%
Direct Selling Active Customers

474.0K

Previous: 576.0K-17.7%
Capital Expenditures

-$7.12M

Previous: -$9.61M+26.0%
Free Cash Flow

$7.81M

Previous: $17.7M-55.9%
Net Income

$14.9M

Previous: $27.3M-45.4%
Operating Income

$22.6M

Previous: $40.8M-44.5%
Gross Profit

$187M

Previous: $224M-16.5%
Cash & Equivalents

$247M

Previous: $249M-0.7%
Total Assets

$556M

No prior period
Stock-Based Comp

$3.08M

No prior period

Revenue & EPS history

USANA · Revenue · Quarterly

$233M

Q3 2022-15%vs Q3 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

The Company is revising its net sales and earnings per share outlook for fiscal year 2022 due to lower Active Customer base and continued expectations of COVID-related, inflationary and economic challenges.

Tailwinds

  • Committed to long-term strategic initiatives.
  • Actively evaluating and implementing actions to minimize the impact of the macro-operating environment.
  • Balance sheet remains debt-free.
  • Expects to generate operating cash flow of approximately $80 million in fiscal 2022.
  • New and modified incentives in various markets and regions to make our overall incentive offering more rewarding and attractive to our sales force.

Headwinds

  • Lower Active Customer base at the end of the third quarter.
  • Continued expectations of COVID-related, inflationary and economic challenges in many markets.
  • Margins will continue to be pressured in the short- to mid-term.
  • The challenging operating environment in Asia Pacific.
  • Strengthening U.S. dollar.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+2.3%

Avg return

Earnings day

+2.0%

Avg return

5 days after

+1.6%

Avg return

30 days after

58%

37 / 64 earnings

Positive

+39.2%

Q2 2015

Best reaction

-24.1%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.3%-9.7%-7.0%
Q3 2025-1.6%-2.8%-6.0%
Q2 2025+4.1%+0.8%+1.5%
Q1 2025+4.9%+13.6%+21.4%
Q4 2024+3.9%-6.2%-13.1%
Q3 2024+4.4%+5.0%+12.3%
Q2 2024-3.7%-7.7%-14.6%
Q1 2024+6.0%+6.0%+8.7%
Q4 2023+7.1%+9.6%+4.6%
Q3 2023-16.7%-17.7%-13.8%
Q2 2023+6.5%+2.1%-0.3%
Q1 2023+4.9%+2.5%-4.4%
Q4 2022+4.7%+4.0%+2.4%
Q3 2022-0.2%-3.0%-6.5%
Q2 2022+1.1%+1.4%-0.5%
Q1 2022-3.6%-2.6%-10.4%
Q4 2021-8.4%-5.2%-10.1%
Q3 2021-8.0%-3.4%+1.3%
Q2 2021-2.3%-6.8%-6.9%
Q1 2021-7.7%-6.4%+9.4%
Q4 2020+15.7%+6.3%+16.4%
Q3 2020+5.1%+10.7%-3.5%
Q2 2020-6.4%-12.4%-8.8%
Q1 2020+17.5%+25.2%+23.8%
Q4 2019+25.3%+28.1%+15.7%
Q3 2019+11.5%+4.8%+1.8%
Q2 2019+0.3%+6.1%+5.7%
Q1 2019+9.4%+2.2%-12.9%
Q4 2018-11.4%-6.5%-18.1%
Q3 2018+3.5%+2.7%+13.0%
Q2 2018+23.9%+18.9%+19.0%
Q1 2018+11.6%+10.3%+22.2%
Q4 2017+5.6%+7.0%+14.4%
Q3 2017+12.5%+9.7%+10.1%
Q2 2017-10.0%-11.2%-7.5%
Q1 2017+6.5%+13.4%+16.4%
Q4 2016-11.6%-8.9%-8.9%
Q3 2016-8.2%-11.5%-13.6%
Q2 2016+11.6%+8.2%+8.4%
Q1 2016+6.2%
Q4 2015-24.1%
Q3 2015-11.6%
Q2 2015+39.2%
Q1 2015+19.2%
Q4 2014-6.6%
Q3 2014+26.5%
Q2 2014-7.8%
Q1 2014-15.2%
Q4 2013+18.8%
Q3 2013-9.6%
Q2 2013-13.3%
Q1 2013+8.1%
Q4 2012+5.8%
Q3 2012+1.7%
Q2 2012+5.4%
Q1 2012+2.0%
Q4 2010-4.2%
Q4 2011-4.2%
Q3 2011-5.4%
Q2 2011-0.3%
Q1 2011-0.3%
Q3 2010-2.0%
Q2 2010+4.3%
Q1 2010+4.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro